The crucial role of the p53 protein in tumor suppression is underscored by the findings that p53 is mutated in over half of all human cancers and that p53-deficient mice universally develop cancer. While p53 suppresses cancer by inducing cell cycle arrest, senescence or apoptosis in response to stress signals, its molecular mechanism of action in vivo remains unclear. p53 displays activity as a transcriptional activator that can induce numerous target genes, but it also has a variety of other biochemical activities, in regulating transcriptional repression, DNA recombination, and mitochondrial membrane integrity. To clarify the p53 molecular activities most relevant for tumor suppression, we previously generated knock-in mice expressing a p53 mutant, p5325,26, that is severely impaired for the transactivation of most genes but retains the ability to robustly transactivate a small set of targets, such as Bax. Moreover, p5325,26 retains biological activity in senescence and tumor suppression. These observations suggest that p5325,26 tumor suppressor function is accounted for by 1) residual strong transactivation of target genes like Bax, 2) very low level expression of most other p53 targets, or 3) another activity of p53. Here, these possibilities will be distinguished by generating and analyzing novel p53 knock-in mutant strains. By examining knock-in mice expressing a mutant totally defective for transactivation through mutation of both p53 transactivation domains, p5325,26,53,54, the importance of transactivation for p53 effector functions of cell cycle arrest, senescence and apoptosis, as well as for tumor suppression in tissues in vivo, will be assessed. Additionally, the roles of transactivation for p53- induced tumor regression in response to cancer therapy will be determined. These studies using knock- in mice, in which mutants are expressed under the control of the native p53 promoter, and in which normal cells can be studied both ex vivo and in the physiological context of the organism, should provide definitive insight into the mechanism of p53 action in tumor suppression and therapeutic responses. Understanding whether activation of the full complement of p53 target genes or a subset of these genes is important for tumor suppression, as well as whether other p53 biochemical activities are important for tumor suppression, will lead to the development of better cancer therapies.

Public Health Relevance

In the US, approximately 1 in every 2-3 individuals will develop cancer, a disease of uncontrolled cellular proliferation that can be fatal. It is therefore very important to understand the basis of this disease in order to be able to more effectively treat and cure it. This research aims to elucidate how p53, a gene important for preventing cancer, acts, with the ultimate goal of devising better prevention and treatment strategies for cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA140875-04
Application #
8590203
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Watson, Joanna M
Project Start
2011-01-01
Project End
2015-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
4
Fiscal Year
2014
Total Cost
$309,806
Indirect Cost
$123,056
Name
Stanford University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Van Nostrand, Jeanine L; Brady, Colleen A; Jung, Heiyoun et al. (2014) Inappropriate p53 activation during development induces features of CHARGE syndrome. Nature 514:228-32
Li, Xingnan; Nadauld, Lincoln; Ootani, Akifumi et al. (2014) Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat Med 20:769-77
Bieging, Kathryn T; Mello, Stephano Spano; Attardi, Laura D (2014) Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 14:359-70
Garcia, Patty B; Attardi, Laura D (2014) Illuminating p53 function in cancer with genetically engineered mouse models. Semin Cell Dev Biol 27:74-85
Kenzelmann Broz, Daniela; Attardi, Laura D (2013) TRP53 activates a global autophagy program to promote tumor suppression. Autophagy 9:1440-2
Attardi, Laura D; Sage, Julien (2013) RB goes mitochondrial. Genes Dev 27:975-9
Mello, S S; Attardi, L D (2013) Not all p53 gain-of-function mutants are created equal. Cell Death Differ 20:855-7
Kenzelmann Broz, Daniela; Spano Mello, Stephano; Bieging, Kathryn T et al. (2013) Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. Genes Dev 27:1016-31
Brady, Colleen A; Jiang, Dadi; Mello, Stephano S et al. (2011) Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 145:571-83
Jiang, Dadi; Brady, Colleen A; Johnson, Thomas M et al. (2011) Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages. Proc Natl Acad Sci U S A 108:17123-8